Probiotics for Irritable Bowel Syndrome
Primary Purpose
Irritable Bowel Syndrome
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Probiotics
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring IBS, Irritable bowel syndrome, Probiotics, Treatment, Adequate relief
Eligibility Criteria
Inclusion Criteria:
- Fulfill ROME III criteria
- age 18-50 years
- signed informed content
Exclusion Criteria:
- Danger signals (fever, anaemia, weightloss, blod in stools, predisposition for CRC or IBD)
- abnormal physical examination
- comorbidity
- abuse
- lacking ability to talk and understand danish
- pregnancy
- For patients > 40 years. Changed bowel habits, with duration > 3 weeks, but < 1 year
Sites / Locations
- Research Unit for General Practice, Department of gastroenterology, Odense University hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Probiotics
Arm Description
Capsules containing maltodextrin.
Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
Outcomes
Primary Outcome Measures
Adequate relief
The patients are asked "In the last seven days, have you had adequate relief of your IBS symptoms?" . They are asked this question every month ( in a monthly letter) for 12 months.
Secondary Outcome Measures
gastrointestinal symptoms
We use the questionnaires GSRS-IBS and GSRS. The patients are asked every month (in monthly letters) for 12 months.
Full Information
NCT ID
NCT01151657
First Posted
June 25, 2010
Last Updated
October 24, 2011
Sponsor
University of Southern Denmark
Collaborators
Mejeribrugets ForskningsFond, Arla Foods
1. Study Identification
Unique Protocol Identification Number
NCT01151657
Brief Title
Probiotics for Irritable Bowel Syndrome
Official Title
Probiotics for Irritable Bowel Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern Denmark
Collaborators
Mejeribrugets ForskningsFond, Arla Foods
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study aims to investigate the effect of probiotics on IBS-patients symptoms compared to placebo, when given for 6 months.
By draw the investigators give IBS patients, in the age of 18-50 years, capsules with either probiotics or placebo. The patients are to take 2x2 capsules / day for 6 months. The patients are followed for 1 year. They are seen after 3, 6 and 12 months, and are followed by means of monthly letters.
The capsules contain 3 different probiotic strains - Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 and Bifidobacterium Bb12. The dose is 2 x 109 - 10 x 109 CFU/capsule.
The hypothesis is, that there is a clinical difference between the group receiving probiotics and the group receiving placebo.
Detailed Description
Background: In management of IBS, no treatments have showed great efficacy. IBS is a non-fatal disease, so safety is a high priority in the choice of treatment. Probiotics is a dietary supplement and have no adverse effects. In some studies it has shown beneficial effect on some of the IBS patients symptoms, but some of the results are questionable. The studies have to be of longer duration, with more patients and the probiotics have to be capsules instead of milk based drinks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
IBS, Irritable bowel syndrome, Probiotics, Treatment, Adequate relief
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Capsules containing maltodextrin.
Arm Title
Probiotics
Arm Type
Experimental
Arm Description
Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Intervention Description
Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo capsules containing maltodextrin
Primary Outcome Measure Information:
Title
Adequate relief
Description
The patients are asked "In the last seven days, have you had adequate relief of your IBS symptoms?" . They are asked this question every month ( in a monthly letter) for 12 months.
Time Frame
Every month for 12 months
Secondary Outcome Measure Information:
Title
gastrointestinal symptoms
Description
We use the questionnaires GSRS-IBS and GSRS. The patients are asked every month (in monthly letters) for 12 months.
Time Frame
Every month for 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Fulfill ROME III criteria
age 18-50 years
signed informed content
Exclusion Criteria:
Danger signals (fever, anaemia, weightloss, blod in stools, predisposition for CRC or IBD)
abnormal physical examination
comorbidity
abuse
lacking ability to talk and understand danish
pregnancy
For patients > 40 years. Changed bowel habits, with duration > 3 weeks, but < 1 year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ove B Schaffalitzky de Muckadell, Dr.Med, Professor
Organizational Affiliation
Department of gastroenterology, Odense University hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Unit for General Practice, Department of gastroenterology, Odense University hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
23957590
Citation
Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbol DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 2013 Oct;48(10):1127-35. doi: 10.3109/00365521.2013.825314. Epub 2013 Aug 19.
Results Reference
derived
Learn more about this trial
Probiotics for Irritable Bowel Syndrome
We'll reach out to this number within 24 hrs